TIGECYCLINE

PeakSM

tigecycline

NDAINTRAVENOUSPOWDER
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Pharmacologic Class:

Tetracycline-class Antibacterial

Clinical Trials (5)

NCT01721408Phase 4Completed

A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection

Started Nov 2012
470 enrolled
Intra-abdominal Infection
NCT01560143Phase 4Completed

Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects

Started Mar 2012
12 enrolled
Obesity
NCT00911573Phase 3Withdrawn

Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects

Started Aug 2011
0
Skin DiseasesInfection
NCT01401023N/ACompleted

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

Started Jul 2011
10 enrolled
DiarrheaClostridium Difficile
NCT01287793Phase 1Completed

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

Started Jan 2011
48 enrolled
Healthy

Loss of Exclusivity

LOE Date
Apr 7, 2033
86 months away
Patent Expiry
Apr 7, 2033

Patent Records (1)

Patent #ExpiryTypeUse Code
9855335
Apr 7, 2033
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers